Literature DB >> 10660642

Evaluation of miconazole activity contained in human serum to hypha of Aspergillus fumigatus.

H Taguchi1, M Miyaji, T Yoshida.   

Abstract

Aspergillus fumigatus is an opportunistic pathogen, especially in an immunocompromised host. This fungus grows in a hyphal form in infected tissues; therefore, new tests to examine hyphal susceptibility are needed. In this study, we measured the mycotic activity of miconazole (MCZ) contained in human serum against A. fumigatus using the BioCell-Tracer method. Three serum samples were obtained from the same patient who was injected with 600 mg b.i.d. MCZ daily for 2 days. The concentrations of MCZ in the serum sample were 8.8, 3.5, and 1.6 micro g/ml, respectively. The serum containing 8.8 micro g/ml of MCZ inhibited hyphal growth 90 minutes after administration, and the hypha stopped growing. The serum containing 3.5 micro g/ml MCZ stopped hypha growth 100 minutes after administration, but re-growth of the hypha was observed at this concentration of MCZ. Serum containing 1.6 micro g/ml did not inhibite hyphal growth, nor did control serum have any inhibitory activity foward hyphae. Based on these results, we conclude that the BioCell-Tracer is a useful method for determining the effects on filamentous fungi of antifungal agents in the serum.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10660642     DOI: 10.3314/jjmm.41.41

Source DB:  PubMed          Journal:  Nihon Ishinkin Gakkai Zasshi        ISSN: 0916-4804


  2 in total

1.  Study on the hyphal responses of Aspergillus fumigatus to the antifungal agent by Bio-Cell Tracer.

Authors:  L Ansheng; H Taguchi; M Miyaji; K Nishimura; S Wu
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

2.  Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.

Authors:  Albrecht Serfling; Johannes Wohlrab; Holger B Deising
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.